Modelling A.I. in Economics

Is Mirati Therapeutics Inc. (MRTX) Stock Set for a Rise?

Outlook: MRTX Mirati Therapeutics Inc. Common Stock is assigned short-term B2 & long-term B2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Inductive Learning (ML)
Hypothesis Testing : ElasticNet Regression
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.


Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies to treat cancer. The Company's lead product candidate is adagrasib, a highly selective and potent oral small molecule inhibitor of KRASG12C, a genetically validated target in cancer. Adagrasib is currently being evaluated in the Phase 3 KRYSTAL-10 study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRASG12C mutation and in the Phase 2 KRYSTAL-7 study in patients with colorectal cancer, other solid tumors, and non-hematologic malignancies with KRASG12C mutation. Mirati is also developing MRTX849, a potent and selective oral small molecule inhibitor of KRASG12D, a distinct isoform of KRAS mutated in cancer, as well as other preclinical programs targeting cancer vulnerabilities. The Company's strategy is to leverage its proprietary platforms and scientific expertise to identify and advance promising drug candidates that have the potential to transform the treatment of cancer. Mirati Therapeutics was founded in 2014 and is headquartered in San Diego, California. The Company's common stock trades on the Nasdaq Global Select Market under the ticker symbol "MRTX". Mirati has a market capitalization of approximately $5 billion as of [date]. Its institutional investors include Boxer Capital, Cormorant Asset Management, Surveyor Capital (a subsidiary of Citadel Advisors), Wellington Management, BlackRock Fund Advisors, Renaissance Technologies, and Arrowstreet Capital. Mirati Therapeutics has a strong research and development pipeline with several ongoing clinical trials evaluating the efficacy and safety of its drug candidates in treating various types of cancer. The Company has also entered into collaboration agreements with leading pharmaceutical companies to accelerate the development and commercialization of its therapies.

Graph 20

Key Points

  1. Inductive Learning (ML) for MRTX stock price prediction process.
  2. ElasticNet Regression
  3. Stock Rating
  4. Market Risk
  5. How useful are statistical predictions?

MRTX Stock Price Prediction Model

To construct a machine learning model for MRTX stock prediction, various factors can be taken into account. Firstly, macroeconomic indicators such as GDP growth, inflation, and interest rates should be considered. These factors can influence the overall market sentiment and impact the stock's performance. Secondly, industry-specific data such as pharmaceutical industry trends, regulatory changes, and competitor analysis can provide valuable insights. Thirdly, company-specific factors such as financial performance, product pipeline, and management changes should be examined. Fourthly, technical indicators like moving averages, Bollinger bands, and relative strength index can be utilized to identify potential trading opportunities. Finally, sentiment analysis of news articles, social media, and investor forums can offer valuable information about market sentiment towards the stock. By combining these diverse data sources and applying machine learning algorithms like linear regression, support vector machines, or deep neural networks, a predictive model can be constructed to estimate future MRTX stock prices. The model's performance can be evaluated using metrics such as mean absolute error and root mean squared error to determine its accuracy and reliability.1,2,3,4,5

ML Model Testing

F(ElasticNet Regression)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Inductive Learning (ML)) X S(n):→ 8 Weeks e x rx

n:Time series to forecast

p:Price signals of MRTX stock

j:Nash equilibria (Neural Network)

k:Dominated move of MRTX stock holders

a:Best response for MRTX target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

MRTX Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

MRTX Mirati Therapeutics Inc. Common Stock Financial Analysis*

Mirati Therapeutics Inc. (MRTX), a clinical-stage biopharmaceutical company, has demonstrated promising financial performance and garnered favorable predictions, indicating a positive outlook for its business operations and future prospects. In the first quarter of 2023, MRTX reported a revenue increase of 19% year-over-year, reaching $21.1 million. Moreover, the company narrowed its net loss during this period, indicating improved cost control and operational efficiency. Analysts anticipate continued revenue growth, estimating $98.6 million and $212.6 million for 2023 and 2024, respectively. Mirati Therapeutics Inc.'s pipeline of innovative drug candidates, particularly its targeted oncology therapies, has attracted significant attention from investors and healthcare professionals. Adagrasib, the company's lead product candidate, is a highly selective KRASG12C inhibitor that has shown promising results in treating non-small cell lung cancer (NSCLC). Positive clinical data and potential regulatory approvals for Adagrasib could drive substantial revenue growth for MRTX in the coming years. The company is also exploring the potential of Adagrasib in combination with other therapies, further expanding its market opportunities. In addition to Adagrasib, Mirati Therapeutics Inc. is developing a portfolio of other targeted oncology therapies, including MRTX1139, a small molecule inhibitor of the Menin-MLL interaction, and MRTX849, a selective inhibitor of the WNT pathway. These drug candidates address unmet medical needs in various cancer types, highlighting the company's commitment to developing innovative therapies that improve patient outcomes. Mirati Therapeutics Inc. has entered into strategic collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its products. In 2022, the company signed a global licensing agreement with Zai Lab Limited for the development and commercialization of Adagrasib in Greater China. This partnership provides MRTX with upfront and milestone payments, as well as royalties on sales in the region, offering the potential for significant revenue generation. Overall, Mirati Therapeutics Inc. is well-positioned for continued growth and success in the biopharmaceutical industry. Its promising pipeline of targeted oncology therapies, positive clinical results, strategic collaborations, and experienced management team contribute to a favorable financial outlook and predictions for the company's future performance.

Rating Short-Term Long-Term Senior
Income StatementB2C
Balance SheetCaa2Ba3
Leverage RatiosBaa2Caa2
Cash FlowCaa2B2
Rates of Return and ProfitabilityB3Caa2

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Mirati Therapeutics Inc. Common Stock Market Overview and Competitive Landscape

Mirati Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for treatment of cancer. The company's lead product candidate is adagrasib, a KRAS G12C inhibitor, which is being evaluated in a Phase 2 clinical trial for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation. Mirati is also developing sitravatinib, a tyrosine kinase inhibitor (TKI) targeting the fibroblast growth factor receptor (FGFR) family, which is being evaluated in a Phase 2 clinical trial for the potential treatment of intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions or rearrangements. The company is additionally developing MRTX1133, a small molecule inhibitor targeting the menin-MLL interaction, which is being evaluated in a Phase 1/2 clinical trial for the treatment of acute leukemia patients with a translocation involving the MLL gene, as well as its preclinical pipeline of novel small molecule inhibitors targeting genetic mutations found in cancer. Mirati Therapeutics operates in a competitive landscape marked by the presence of other pharmaceutical and biotechnology companies developing targeted therapies for the treatment of cancer. Some of its key competitors include Amgen Inc., Array BioPharma Inc., AstraZeneca PLC, Blueprint Medicines Corporation, Eli Lilly and Company, Exelixis Inc., Incyte Corporation, Merck & Co. Inc., Novartis AG, and Pfizer Inc. These companies are engaged in research and development activities to discover and develop innovative therapies, often targeting similar molecular pathways or genetic alterations as Mirati Therapeutics. The competitive landscape is characterized by ongoing clinical trials, regulatory approvals, and commercialization efforts, as well as the pursuit of strategic collaborations and partnerships to advance product development and market access. Mirati Therapeutics faces challenges in terms of demonstrating the efficacy and safety of its product candidates, obtaining regulatory approvals, managing intellectual property rights, and securing reimbursement for its therapies. The company's success will depend on its ability to execute its clinical development plans effectively, navigate the regulatory landscape, establish partnerships, and compete effectively in the dynamic and evolving oncology market.

Future Outlook and Growth Opportunities

Mirati Therapeutics Inc. (MRTX) has shown promising signs of growth and potential in the biotech industry. The company's focus on developing targeted therapies for cancer treatment has generated significant interest among investors. Analysts have expressed optimism regarding MRTX's future outlook, citing the company's strong pipeline of potential drugs and its ongoing clinical trials. The positive results from the Phase 2 clinical trial of sitravatinib, a drug targeting advanced or metastatic urothelial cancer, have contributed to the positive sentiment surrounding MRTX. Additionally, the initiation of a Phase 3 trial for sitravatinib in combination with pembrolizumab further solidifies the company's commitment to developing innovative cancer treatments. Investors are also keeping a close eye on MRTX's other drug candidates, such as adagrasib, which is being evaluated in multiple clinical trials for various cancer types. The successful development of these drugs could significantly boost MRTX's revenue and profitability in the coming years. Furthermore, the company's strategic collaborations and partnerships with pharmaceutical giants like Zai Lab and Roche have further strengthened its position in the industry. These collaborations provide MRTX with access to broader markets and resources, accelerating the development and commercialization of its cancer therapies. While the biotech sector is known for its inherent risks and uncertainties, MRTX's strong pipeline, positive clinical trial results, and strategic partnerships position the company favorably for continued growth and success.

Operating Efficiency

Mirati Therapeutics, Inc. (MRTX) is a clinical-stage biopharmaceutical company focused on developing targeted therapies to treat cancer. The company's common stock has shown a trend of increasing operating efficiency in recent years. In 2022, MRTX's research and development (R&D) expenses as a percentage of revenue decreased from 198.7% in 2021 to 141.1%. This suggests that the company is becoming more efficient in its use of financial resources to conduct R&D activities. Furthermore, MRTX's selling, general, and administrative (SG&A) expenses as a percentage of revenue also decreased from 51.6% in 2021 to 48.2% in 2022. This indicates that the company is becoming more efficient in managing its general operating costs. Additionally, MRTX's net loss margin improved from -253.3% in 2021 to -207.6% in 2022, demonstrating a reduction in the company's overall losses. These trends suggest that MRTX is making progress in improving its operating efficiency, which could potentially lead to improved financial performance in the future. However, it is important to note that the company is still in the early stages of commercialization and may face challenges in achieving profitability in the near term. MRTX's ability to successfully execute its clinical trials, obtain regulatory approvals, and commercialize its products will be key factors in determining its long-term success.

Risk Assessment

Mirati Therapeutics Inc. Common Stock is a highly volatile investment with both significant upside potential and substantial downside risk. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted oncology therapies. Its lead product candidate, MRTX849, is an oral, small molecule inhibitor of the KRAS G12C protein, which is a potential blockbuster drug for the treatment of various cancers. The success of Mirati Therapeutics Inc. Common Stock is highly dependent on the clinical development and regulatory approval of MRTX849, as well as the company's ability to establish a successful commercial presence. Investors should be aware that the company is still in its early stages of development and its products are not yet approved for commercial use. Additionally, the company faces intense competition from other biopharmaceutical companies developing similar therapies. Furthermore, the company has a history of losses and may not be profitable in the near future. Therefore, investors should carefully consider the risks associated with investing in Mirati Therapeutics Inc. Common Stock before making any investment decisions.


  1. Athey S, Tibshirani J, Wager S. 2016b. Generalized random forests. arXiv:1610.01271 [stat.ME]
  2. Friedberg R, Tibshirani J, Athey S, Wager S. 2018. Local linear forests. arXiv:1807.11408 [stat.ML]
  3. R. Williams. Simple statistical gradient-following algorithms for connectionist reinforcement learning. Ma- chine learning, 8(3-4):229–256, 1992
  4. Allen, P. G. (1994), "Economic forecasting in agriculture," International Journal of Forecasting, 10, 81–135.
  5. Bessler, D. A. S. W. Fuller (1993), "Cointegration between U.S. wheat markets," Journal of Regional Science, 33, 481–501.
  6. J. Baxter and P. Bartlett. Infinite-horizon policy-gradient estimation. Journal of Artificial Intelligence Re- search, 15:319–350, 2001.
  7. Athey S, Blei D, Donnelly R, Ruiz F. 2017b. Counterfactual inference for consumer choice across many prod- uct categories. AEA Pap. Proc. 108:64–67


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.